Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II)

Lawrence Appel, Patricia R. Hebert, Jerome D. Cohen, Eva Obarzanek, Monica Yamamoto, Julie Buring, Victor Stevens, Kent Kirchner, Nemat O. Borhani

Research output: Contribution to journalArticle

Abstract

Phase II of the Trials of Hypertension Prevention (TOHP II) is a multicenter, controlled clinical trial designed to test whether weight loss, a reduced sodium intake, or a combinatian of weight loss and a reduced sodium intake will lower blood pressure (BP) and prevent the occurrence of hypertension. The study population consists of middle-aged, moderately overweight individuals with a diastolic BP between 83 and 89 mm Hg. Of the 2382 randomized participants, 816 (34%) are female and 494 (21%) are from a racial or ethnic minority background. At baseline, mean dietary intakes of sodium, based on measurements of 24-hour urinary excretion, were 199 mmol/d in men and 154 mmol/d in women. The average body mass index was 30.9 kg/m2. Across the four randomized groups, there was no substantial imbalance in the distribution of baseline variables; however, the mean age in the four groups was slightly but significantly different (range: 43.2 to 44.2 years, P = 0.02). A comparison of baseline characteristics of TOHP II participants with those of participants in three other primary prevention trials reveals a high level of mean dietary sodium intake in each study. Data reported in this article indicate that any subsequent differences in BP among the randomized groups are unlikely to result from maldistribution of known confounding variables at baseline. Finally, because of the high prevalence of overweight and excessive sodium intake in the United States, results from TOHP II should be broadly applicable to the general population.

Original languageEnglish (US)
Pages (from-to)149-155
Number of pages7
JournalAnnals of Epidemiology
Volume5
Issue number2
DOIs
StatePublished - 1995

Fingerprint

Blood Pressure
Hypertension
Dietary Sodium
Sodium
Weight Loss
Confounding Factors (Epidemiology)
Controlled Clinical Trials
Primary Prevention
Population
Body Mass Index

Keywords

  • clinical trial
  • comparative study
  • Hypertension
  • prevention

ASJC Scopus subject areas

  • Epidemiology
  • Medicine(all)
  • Public Health, Environmental and Occupational Health

Cite this

Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II). / Appel, Lawrence; Hebert, Patricia R.; Cohen, Jerome D.; Obarzanek, Eva; Yamamoto, Monica; Buring, Julie; Stevens, Victor; Kirchner, Kent; Borhani, Nemat O.

In: Annals of Epidemiology, Vol. 5, No. 2, 1995, p. 149-155.

Research output: Contribution to journalArticle

Appel, L, Hebert, PR, Cohen, JD, Obarzanek, E, Yamamoto, M, Buring, J, Stevens, V, Kirchner, K & Borhani, NO 1995, 'Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II)', Annals of Epidemiology, vol. 5, no. 2, pp. 149-155. https://doi.org/10.1016/1047-2797(94)00059-3
Appel, Lawrence ; Hebert, Patricia R. ; Cohen, Jerome D. ; Obarzanek, Eva ; Yamamoto, Monica ; Buring, Julie ; Stevens, Victor ; Kirchner, Kent ; Borhani, Nemat O. / Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II). In: Annals of Epidemiology. 1995 ; Vol. 5, No. 2. pp. 149-155.
@article{555625211daa4253b887065ca843dbc7,
title = "Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II)",
abstract = "Phase II of the Trials of Hypertension Prevention (TOHP II) is a multicenter, controlled clinical trial designed to test whether weight loss, a reduced sodium intake, or a combinatian of weight loss and a reduced sodium intake will lower blood pressure (BP) and prevent the occurrence of hypertension. The study population consists of middle-aged, moderately overweight individuals with a diastolic BP between 83 and 89 mm Hg. Of the 2382 randomized participants, 816 (34{\%}) are female and 494 (21{\%}) are from a racial or ethnic minority background. At baseline, mean dietary intakes of sodium, based on measurements of 24-hour urinary excretion, were 199 mmol/d in men and 154 mmol/d in women. The average body mass index was 30.9 kg/m2. Across the four randomized groups, there was no substantial imbalance in the distribution of baseline variables; however, the mean age in the four groups was slightly but significantly different (range: 43.2 to 44.2 years, P = 0.02). A comparison of baseline characteristics of TOHP II participants with those of participants in three other primary prevention trials reveals a high level of mean dietary sodium intake in each study. Data reported in this article indicate that any subsequent differences in BP among the randomized groups are unlikely to result from maldistribution of known confounding variables at baseline. Finally, because of the high prevalence of overweight and excessive sodium intake in the United States, results from TOHP II should be broadly applicable to the general population.",
keywords = "clinical trial, comparative study, Hypertension, prevention",
author = "Lawrence Appel and Hebert, {Patricia R.} and Cohen, {Jerome D.} and Eva Obarzanek and Monica Yamamoto and Julie Buring and Victor Stevens and Kent Kirchner and Borhani, {Nemat O.}",
year = "1995",
doi = "10.1016/1047-2797(94)00059-3",
language = "English (US)",
volume = "5",
pages = "149--155",
journal = "Annals of Epidemiology",
issn = "1047-2797",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II)

AU - Appel, Lawrence

AU - Hebert, Patricia R.

AU - Cohen, Jerome D.

AU - Obarzanek, Eva

AU - Yamamoto, Monica

AU - Buring, Julie

AU - Stevens, Victor

AU - Kirchner, Kent

AU - Borhani, Nemat O.

PY - 1995

Y1 - 1995

N2 - Phase II of the Trials of Hypertension Prevention (TOHP II) is a multicenter, controlled clinical trial designed to test whether weight loss, a reduced sodium intake, or a combinatian of weight loss and a reduced sodium intake will lower blood pressure (BP) and prevent the occurrence of hypertension. The study population consists of middle-aged, moderately overweight individuals with a diastolic BP between 83 and 89 mm Hg. Of the 2382 randomized participants, 816 (34%) are female and 494 (21%) are from a racial or ethnic minority background. At baseline, mean dietary intakes of sodium, based on measurements of 24-hour urinary excretion, were 199 mmol/d in men and 154 mmol/d in women. The average body mass index was 30.9 kg/m2. Across the four randomized groups, there was no substantial imbalance in the distribution of baseline variables; however, the mean age in the four groups was slightly but significantly different (range: 43.2 to 44.2 years, P = 0.02). A comparison of baseline characteristics of TOHP II participants with those of participants in three other primary prevention trials reveals a high level of mean dietary sodium intake in each study. Data reported in this article indicate that any subsequent differences in BP among the randomized groups are unlikely to result from maldistribution of known confounding variables at baseline. Finally, because of the high prevalence of overweight and excessive sodium intake in the United States, results from TOHP II should be broadly applicable to the general population.

AB - Phase II of the Trials of Hypertension Prevention (TOHP II) is a multicenter, controlled clinical trial designed to test whether weight loss, a reduced sodium intake, or a combinatian of weight loss and a reduced sodium intake will lower blood pressure (BP) and prevent the occurrence of hypertension. The study population consists of middle-aged, moderately overweight individuals with a diastolic BP between 83 and 89 mm Hg. Of the 2382 randomized participants, 816 (34%) are female and 494 (21%) are from a racial or ethnic minority background. At baseline, mean dietary intakes of sodium, based on measurements of 24-hour urinary excretion, were 199 mmol/d in men and 154 mmol/d in women. The average body mass index was 30.9 kg/m2. Across the four randomized groups, there was no substantial imbalance in the distribution of baseline variables; however, the mean age in the four groups was slightly but significantly different (range: 43.2 to 44.2 years, P = 0.02). A comparison of baseline characteristics of TOHP II participants with those of participants in three other primary prevention trials reveals a high level of mean dietary sodium intake in each study. Data reported in this article indicate that any subsequent differences in BP among the randomized groups are unlikely to result from maldistribution of known confounding variables at baseline. Finally, because of the high prevalence of overweight and excessive sodium intake in the United States, results from TOHP II should be broadly applicable to the general population.

KW - clinical trial

KW - comparative study

KW - Hypertension

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=0028947312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028947312&partnerID=8YFLogxK

U2 - 10.1016/1047-2797(94)00059-3

DO - 10.1016/1047-2797(94)00059-3

M3 - Article

C2 - 7795833

AN - SCOPUS:0028947312

VL - 5

SP - 149

EP - 155

JO - Annals of Epidemiology

JF - Annals of Epidemiology

SN - 1047-2797

IS - 2

ER -